GEN Exclusives

More »

GEN News Highlights

More »
Nov 18, 2009

Evotec Awarded Roughly $3.74 by German Government to Hunt for Neuroprotective Compounds

  • Evotec received a research grant of up to €2.5 million (about $3.74 million) from the German government to fund R&D on serine racemase, a potential target in the field of neuroprotection. The grant will fund the company’s use of its compound library and fragment-based drug discovery platform to progress the project toward the clinic.

    The money was awarded as part of Evotec’s involvement in the German government-supported Neu2 consortium. The consortium is focused on developing therapeutics against neurodegenerative diseases including multiple sclerosis.

    Partners include Evotec, Merck Serono, the European ScreeningPort, Bionamics, and the University Medical Center Hamburg-Eppendorf.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?